<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438996</url>
  </required_header>
  <id_info>
    <org_study_id>H01_04E1TP</org_study_id>
    <nct_id>NCT01438996</nct_id>
  </id_info>
  <brief_title>Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults</brief_title>
  <official_title>A Phase 2, Open-label, Single-center, Extension Study to Evaluate the Booster Response Induced by Vi-CRM197 After Priming With Either Vi-CRM197 or Typherix Administered in Adult Subjects in H01_04TP Study (NCT01193907)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi
      antibody response following secondary vaccination with the Novartis Vaccines Institute for
      Global Health (NVGH) Vi-CRM197 vaccine in healthy adults previously vaccinated with either
      the NVGH Vi-CRM197 or Vi-polysaccharide (Typherix) in the H01_04TP study (NCT01193907) and
      the immunogenicity and the kinetics of the anti-Vi antibody response following primary
      vaccination with the NVGH Vi-CRM197 vaccine in naïve healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Vi ELISA Geometric Mean Concentration (GMC)</measure>
    <time_frame>At 3 days after vaccination</time_frame>
    <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 3 after vaccination as as measured by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Vi ELISA GMC</measure>
    <time_frame>At 7 days after vaccination</time_frame>
    <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 7 after vaccination as as measured by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Vi ELISA GMC</measure>
    <time_frame>At 28 days after vaccination</time_frame>
    <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 28 after vaccination as as measured by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</measure>
    <time_frame>At 3 days after vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</measure>
    <time_frame>At 7 days after vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</measure>
    <time_frame>At 28 days after vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any (Local, Systemic and Other) Post Vaccination Reaction</measure>
    <time_frame>During the 7-day period after vaccination</time_frame>
    <description>Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia, fatigue and fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting AE</measure>
    <time_frame>During the 28-day period after vaccination</time_frame>
    <description>AE during 28 days after vaccination(including solicited reactions during 7 days after vaccination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the 28-day period after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>NVGH Vi-CRM/NVGH Vi-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-PS/NVGH Vi-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVGH Vi-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NVGH Vi-CRM197</intervention_name>
    <description>Vi-CRM197 glycoconjugated vaccine</description>
    <arm_group_label>NVGH Vi-CRM/NVGH Vi-CRM</arm_group_label>
    <arm_group_label>Vi-PS/NVGH Vi-CRM</arm_group_label>
    <arm_group_label>NVGH Vi-CRM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        All Subjects:

          1. Males and females of age ≥18 to ≤42 years.

          2. Individuals, who, after the nature of the study have been explained to them, have
             given written consent according to local regulatory requirements.

          3. Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

          4. If women, use of birth control one month before study start, a negative pregnancy test
             and willingness to use birth control measures for the entire study duration.

             H01_04TP subjects only:

          5. Individuals who previously participated in the H01_04TP study and were vaccinated with
             either NVGH Vi-CRM197 (5μg) or with the licensed Vi-PS.

          6. Individuals who have received no Vi vaccination subsequent to the one received in the
             H01_04TP study.

        Inclusion criteria

        All subjects:

          1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may interfere with the subject's ability to
             participate in the study.

          2. Individuals with any progressive or severe neurological disorder, seizure disorder or
             Guillain-Barré syndrome.

          3. Individuals who are not able to understand and to follow all required study procedures
             for the whole period of the study.

          4. Individuals with history of any illness that, in the opinion of the investigator, pose
             additional risk to the subjects due to participation in the study.

          5. Individuals with known or suspected HIV infection or HIV related disease, with history
             of an autoimmune disorder or any other known or suspected impairment /alteration of
             the immune system, or under immunosuppressive therapy including use of systemic
             corticosteroids or chronic use of inhaled high-potency corticosteroids within the
             previous 30 days, or were in chemotherapy treatment within the past 6 months.

          6. Individuals with a known bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time.

          7. Individuals with any serious chronic or progressive disease according to judgment of
             the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or
             hepatic disease).

          8. Individuals who have any malignancy or lymphoproliferative disorder.

          9. Individuals with history of allergy to vaccine components.

         10. Individuals participating in any clinical trial with another investigational product
             30 days prior to first study visit or intent to participate in another clinical study
             at any time during the conduct of this study.

         11. Individuals who received any vaccines within 4 weeks prior to enrolment in this study
             or who are planning to receive any vaccine within 4 weeks from the study vaccine

         12. Individuals who have received blood, blood products and/or plasma derivatives
             including parenteral immunoglobulin preparations in the past 12 weeks.

         13. Individuals who are part of study personnel or close family members to the personnel
             conducting this study.

         14. Individuals with body temperature &gt; 38.0 degrees Celsius within 3 days of intended
             study immunization.

         15. BMI &gt; 35 kg/m2.

         16. Individuals with history of substance or alcohol abuse within the past 2 years.

         17. Women who are pregnant or breast-feeding or of childbearing age who have not used any
             birth control measure one month prior to study start or do not plan to use acceptable
             birth control measures, for the duration of the study.

         18. Females with history of stillbirth, neonatal loss, or previous infant with anomaly.

         19. Individuals who have a previously ascertained or suspected disease caused by S. Typhi.

         20. Individuals who have had household contact with/and or intimate exposure to an
             individual with laboratory confirmed S. Typhi.

         21. Any condition which, in the opinion of the investigator may interfere with the
             evaluation of the study objectives.

             Naïve subjects only:

         22. Individuals who have previously received any vaccine against typhoid fever (either
             oral live attenuated or injectable vaccines)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Van Damme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for the Evaluation of Vaccination (CEV)</name>
      <address>
        <city>Antwerp</city>
        <state>Wilrijk</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <results_first_submitted>December 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2014</results_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Typhoid fever</keyword>
  <keyword>Glycoconjugate vaccine</keyword>
  <keyword>Vi polysaccharide</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled: 17 OCT 11, Last subject completed: 13 DEC 11.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
        </group>
        <group group_id="P2">
          <title>Vi-PS/NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
        </group>
        <group group_id="P3">
          <title>NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not meeting Inclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
        </group>
        <group group_id="B2">
          <title>Vi-PS/NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
        </group>
        <group group_id="B3">
          <title>NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="5.8"/>
                    <measurement group_id="B2" value="26.3" spread="6.6"/>
                    <measurement group_id="B3" value="26.0" spread="6.2"/>
                    <measurement group_id="B4" value="25.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA Geometric Mean Concentration (GMC)</title>
        <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 3 after vaccination as as measured by enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>At 3 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA Geometric Mean Concentration (GMC)</title>
          <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 3 after vaccination as as measured by enzyme-linked immunosorbent assay (ELISA)</description>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="O2" value="31" lower_limit="16" upper_limit="60"/>
                    <measurement group_id="O3" value="3.22" lower_limit="1.99" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA GMC</title>
        <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 7 after vaccination as as measured by ELISA</description>
        <time_frame>At 7 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA GMC</title>
          <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 7 after vaccination as as measured by ELISA</description>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="42" upper_limit="102"/>
                    <measurement group_id="O2" value="40" lower_limit="24" upper_limit="67"/>
                    <measurement group_id="O3" value="20" lower_limit="10" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA GMC</title>
        <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 28 after vaccination as as measured by ELISA</description>
        <time_frame>At 28 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA GMC</title>
          <description>To evaluate the immunogenicity and the kinetics of the immune response induced by one dose of NVGH Vi-CRM197 at study day 28 after vaccination as as measured by ELISA</description>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="28" upper_limit="69"/>
                    <measurement group_id="O2" value="50" lower_limit="35" upper_limit="71"/>
                    <measurement group_id="O3" value="111" lower_limit="78" upper_limit="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</title>
        <time_frame>At 3 days after vaccination as compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</title>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</title>
        <time_frame>At 7 days after vaccination as compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</title>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O3" value="60" lower_limit="36" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</title>
        <time_frame>At 28 days after vaccination as compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers</title>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O2" value="17" lower_limit="2" upper_limit="48"/>
                    <measurement group_id="O3" value="100" lower_limit="83" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any (Local, Systemic and Other) Post Vaccination Reaction</title>
        <description>Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia, fatigue and fever.</description>
        <time_frame>During the 7-day period after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any (Local, Systemic and Other) Post Vaccination Reaction</title>
          <description>Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia, fatigue and fever.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting AE</title>
        <description>AE during 28 days after vaccination(including solicited reactions during 7 days after vaccination)</description>
        <time_frame>During the 28-day period after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting AE</title>
          <description>AE during 28 days after vaccination(including solicited reactions during 7 days after vaccination)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <time_frame>During the 28-day period after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS/NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
          </group>
          <group group_id="O3">
            <title>NVGH Vi-CRM</title>
            <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NVGH Vi-CRM/NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study</description>
        </group>
        <group group_id="E2">
          <title>Vi-PS/NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study</description>
        </group>
        <group group_id="E3">
          <title>NVGH Vi-CRM</title>
          <description>One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nasopharingitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results, provided that he furnishes NVGH with a copy of the proposed publication for NVGH's review and comment, at least 1 month prior to submission to a publisher or disclosure to any third party.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Audino Podda</name_or_title>
      <organization>Novartis Vaccines Institute for Global Health</organization>
      <phone>+39 0577 243496</phone>
      <email>audino.podda@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

